-
糖尿病是多种因素导致胰岛素分泌不足、靶细胞对胰岛素敏感性下降的慢性高血糖内分泌代谢性疾病[1]。长期的高血糖将导致肾、眼、心脏、血管等组织慢性损伤, 严重威胁病人身心健康[2]。目前认为, 糖尿病两大生理病理发病机制为胰岛素抵抗和胰岛β细胞功能低下[3]; 炎症学说在2型糖尿病发病机制中越来越受到重视, 炎症因子过表达可能与胰岛素抵抗相关[4]。随着糖尿病病人的逐渐增多, 控制血糖至正常水平和避免传统药物的不良反应成为当前治疗糖尿病的主要问题, 二肽基肽酶-4 (depeptidyl peptidase 4, DPP-4)抑制剂是治疗2型糖尿病的新型药物, 研究证明能够控制血糖和改善胰岛素抵抗的作用[5]。本研究主要探讨DPP-4抑制剂维格列汀对2型糖尿病病人胰岛素抵抗及炎症因子的影响。
-
2组治疗前的FBG、2hPBG、HbA1c、Fins、HOMA-IR比较差异均无统计学意义(P>0.05);治疗后对照组FBG、2hPBG、HbA1c较治疗前降低(P < 0.01), 观察组FBG、2hPBG、HbA1c、Fins、HOMR-IR均较治疗前降低(P < 0.01);且治疗后观察组各项指标均低于对照组(P < 0.01)(见表 1)。
分组 n FBG/(mmol/L) 2hPBG/(mmol/L) HbA1c/% Fins/(μU/mL) H0MA-IR 治疗前 对照组 48 9.05±2.11 12.81±2.57 8.42±1.43 8.79±2.37 3.14±1.16 观察组 48 9.08±2.01 13.13±2.69 8.32±1.35 8.73±2.61 3.21±1.23 t - 0.07 0.60 0.35 0.12 0.29 P - >0.05 >0.05 >0.05 >0.05 >0.05 治疗后 对照组 48 7.17±2.32** 10.61±2.63** 7.42±1.54** 8.21±2.52 3.02±1.13 观察组 48 6.18±2.21** 8.25±2.56** 6.01±1.25** 6.61±1.83** 2.06±1.01** t - 2.14 4.45 4.93 3.56 4.39 P - < 0.05 < 0.01 < 0.01 < 0.01 < 0.01 组内配对t检验:**P < 0.01 表 1 2组治疗前后胰岛素抵抗变化情况比较
-
2组治疗前hs-CRP、IL-6和TNF-α比较差异均无统计学意义(P>0.05);治疗后2组各指标均下降, 对照组IL-6和TNF-α较治疗前显著降低(P < 0.01), 观察组hs-CRP、IL-6和TNF-α均较治疗前显著降低(P < 0.01);且治疗后观察组各项指标均显著低于对照组(P < 0.01)(见表 2)。
分组 n hs-CRP/(mg/L) IL-6/(μg/mL) TNF-α/(μg/mL) 治疗前 对照组 48 11.03±2.81 88.21±17.13 102.45±19.32 观察组 48 10.92±3.21 86.24±15.71 105.73±20.48 t - 0.18 0.59 0.81 P - >0.05 >0.05 >0.05 治疗后 对照组 48 10.43±2.55 80.65±12.42** 97.21±18.54** 观察组 48 6.13±1.65** 62.62±10.43** 83.32±16.51** t - 2.14 4.45 4.93 P - < 0.05 < 0.01 < 0.01 组内配对t检验:**P < 0.01 表 2 2组治疗前后炎症因子变化($\bar{x}\pm s$)
维格列汀对2型糖尿病病人胰岛素抵抗指数、超敏C反应蛋白、肿瘤坏死因子-α和白细胞介素-6的影响
Effect of vildagliptin on the levels of HOMA-IR, hs-CRP, TNF-α and IL-6 in patients with type 2 diabetes mellitus
-
摘要:
目的探索维格列汀对2型糖尿病病人胰岛素抵抗指数(HOMA-IR)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)的影响。 方法选取96例2型糖尿病病人,随机分为对照组和观察组,各48例。对照组病人服用盐酸二甲双胍片,观察组病人在对照组二甲双胍基础上给予维格列汀;检测空腹血糖(FBG)、餐后2 h血糖(2hPBG)、糖化血红蛋白(HbA1c)、空腹胰岛素(Fins)、HOMA-IR。 结果2组治疗前的FBG、2hPBG、HbA1c、Fins、HOMA-IR比较差异均无统计学意义(P>0.05);治疗后2组各指标均下降,对照组FBG、2hPBG、HbA1c较治疗前降低(P < 0.01),观察组FBG、2hPBG、HbA1c、Fins、HOMR-IR均较治疗前降低(P < 0.01);且治疗后观察组各项指标均低于对照组(P < 0.01)。2组治疗前hs-CRP、IL-6和TNF-α比较差异均无统计学意义(P>0.05),治疗后对照组IL-6和TNF-α较治疗前明显降低(P < 0.01),观察组hs-CRP、IL-6和TNF-α均较治疗前明显降低(P < 0.01);且治疗后观察组各项指标均低于对照组(P < 0.01)。 结论维格列汀能够改善2型糖尿病病人的胰岛素抵抗,同时可显著降低病人的炎症因子水平,具有较高的临床价值。 Abstract:ObjectiveTo explore the effects of vildagliptin on the levels of insulin resistance index(HOMA-IR), high sensitive C reactive protein(hs-CRP), tumor necrosis factor alpha(TNF-α) and interleukin -6(IL-6) in patients with type 2 diabetes mellitus. MethodsNinety-six patients with type 2 diabetes mellitus were randomly divided into the control group and observation group(48 cases in each group).The control group was treated with metformin hydrochloride tablets, and the observation group was treated with vildagliptin based on the control group.The levels of fasting blood glucose(FBG), 2 h postprandial blood glucose(2hPBG), glycosylated hemoglobin(HbA1c), fasting insulin (Fins) and HOMA-IR were detected in two groups. ResultsThe differences of the levels of FBG, 2hPBG, HbA1c, Fins and HOMA-IR between two groups before treatment were not statistically significant(P>0.05).After treatment, these indictors in two groups decreased, the levels of FBG, 2hPBG and HbA1c in control group decreased compared with before treatment(P < 0.01), the levels of FBG, 2hPBG, HbA1c, Fins and HOMR-IR in observation group decreased compared with before treatment, and these indictors in observation group were lower than those in control group(P < 0.01).The differences of the levels of hs-CRP, IL-6and TNF-α between two groups before treatment were not statistically significant(P>0.05).After treatment, the levels of IL-6 and TNF-α in control group significantly decreased compared with before treatment(P < 0.01), the levels of hs-CRP, IL-6 and TNF-α in observation group significantly decreased compared with before treatment, and these indictors in observation group were lower than those in control group(P < 0.01). ConclusionsVildaglipti can improve the insulin resistance, and significantly reduce the level of inflammatory factors in type 2 diabetic patients, which has high clinical value. -
Key words:
- type 2 diabetes mellitus /
- vildaglipti /
- insulin resistance /
- inflammatory factor
-
表 1 2组治疗前后胰岛素抵抗变化情况比较
分组 n FBG/(mmol/L) 2hPBG/(mmol/L) HbA1c/% Fins/(μU/mL) H0MA-IR 治疗前 对照组 48 9.05±2.11 12.81±2.57 8.42±1.43 8.79±2.37 3.14±1.16 观察组 48 9.08±2.01 13.13±2.69 8.32±1.35 8.73±2.61 3.21±1.23 t - 0.07 0.60 0.35 0.12 0.29 P - >0.05 >0.05 >0.05 >0.05 >0.05 治疗后 对照组 48 7.17±2.32** 10.61±2.63** 7.42±1.54** 8.21±2.52 3.02±1.13 观察组 48 6.18±2.21** 8.25±2.56** 6.01±1.25** 6.61±1.83** 2.06±1.01** t - 2.14 4.45 4.93 3.56 4.39 P - < 0.05 < 0.01 < 0.01 < 0.01 < 0.01 组内配对t检验:**P < 0.01 表 2 2组治疗前后炎症因子变化(
)$\bar{x}\pm s$ 分组 n hs-CRP/(mg/L) IL-6/(μg/mL) TNF-α/(μg/mL) 治疗前 对照组 48 11.03±2.81 88.21±17.13 102.45±19.32 观察组 48 10.92±3.21 86.24±15.71 105.73±20.48 t - 0.18 0.59 0.81 P - >0.05 >0.05 >0.05 治疗后 对照组 48 10.43±2.55 80.65±12.42** 97.21±18.54** 观察组 48 6.13±1.65** 62.62±10.43** 83.32±16.51** t - 2.14 4.45 4.93 P - < 0.05 < 0.01 < 0.01 组内配对t检验:**P < 0.01 -
[1] 侯清涛, 李芸, 李舍予.全球糖尿病疾病负担现状[J].中国糖尿病杂志, 2016, 24(1):92. doi: 10.3969/j.issn.1006-6187.2016.01.023 [2] 何春秀, 郝桂荣, 张会君, 等.老年2型糖尿病患者医学应对方式及影响因素研究[J].中国全科医学, 2015, 15(5):525. doi: 10.3969/j.issn.1007-9572.2015.05.010 [3] 张霞.2型糖尿病的临床发病机制分析[J].齐齐哈尔医学院学报, 2013, 34(18):2673. doi: 10.3969/j.issn.1002-1256.2013.18.013 [4] 张黎明, 高凌.炎症细胞因子在2型糖尿病发病机制中的研究进展[J].重庆医学, 2016, 45(8):1113. doi: 10.3969/j.issn.1671-8348.2016.08.038 [5] 刘琼, 何翠英, 卫家芬.DPP-4抑制剂治疗2型糖尿病的研究进展及临床应用[J].实用药物与临床, 2015, 18(7):856. [6] 廖涌.中国糖尿病的流行病学现状及展望[J].重庆医科大学学报, 2015, 40(7):1042. [7] DEACON CF, HOLST JJ.Dipptidyl peptidase 4 inhibitors:a promising new therapeutic approach for the management of type 2 diabetes[J].Int J biochem Cell Bio, 2006, 38(5/6):831. [8] AMORI RE, LAU J, PITTAS AG.Efficacy and safety of incretin therapy in type 2 diabetes:systematic review and meta-analysis[J].JAMA, 2007, 298:194. doi: 10.1001/jama.298.2.194 [9] ILKOVA H, GLASER B, TUNÇKALE A, et al.Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment[J].Diabetes Care, 1997, 20(9):1353. doi: 10.2337/diacare.20.9.1353 [10] HOTAMISLIGIL GS.Inflammatory pathways and insulin action[J].Int J Obes Relat Metab Disord, 2003, 27(Suppl)3:S53.[1] HEIDARI J, MIERSWA T, HASENBRING M, et al.Low back pain in athletes and non-athletes:a group comparison of basic pain parameters and impact on sports activity[J].Sport Sci Health, 2016, 12(3):1. doi: 10.1038/sj.ijo.0802502